Roche Holding


BIC22 takeaways

20/09/22 -"During BIC22, Roche confirmed the solid (recovery) momentum in Core Pharmas, along with ample support from less severe biosimilar headwinds and COVID-19 business’s moderation, confidence with ..."

Pages
69
Language
English
Published on
20/09/22
You may also be interested by these reports :
29/09/22
Reality digested – Looking ahead

28/09/22
Novavax and Siegfried extend aseptic fill & finish collaboration for Novavax’s protein-based coronavirus vaccine Nuvaxovid

23/09/22
Novartis again shared a reassuring outlook, with promising sales growth and margin expansion targets. The only difference now is that the firm has ...

22/09/22
11th Baader Investment Conference: Positive outlook for the mid-/long-term

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO